Biotech entity
Every one of those 3 sits in a single category, pharma. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. Aedes albopictus is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories.
Last mentioned: Aug 3, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, pharma. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. Aedes albopictus is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. That works out to roughly 0.1 stories per week across a 166-day span. At 6.3, the average consequence score sits above the same-window beat average of 6.2. This profile follows 3 Biotech stories mentioning European Medicines Agency (EMA) across the period from February 19, 2026 to August 3, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 659 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering European Medicines Agency (EMA). Shared-story counts are live from our verified record — not editorial picks.
High Court grants permission for judicial review
Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.
NCPE pharmacoeconomic evaluation completed
The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.
HSE reimbursement application filed
Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.
European market authorisation
The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.
Diagnosis with Friedreich's ataxia
Emily Felix, then 12 years old, is diagnosed with the rare, progressive neuromuscular disease.
Biogen’s orphan drug for Friedreich’s ataxia, approved by the EMA since February 2024, remains mired in Irish reimbursement ambiguity, prompting a patient’s judicial review and highlighting the EU’s fragmented market access for novel therapies.
With zero critical findings on its fourth EMA GMP certification, WuXi Biologics now empowers 13 biotech clients to commercialize 19 biologics in Europe. This milestone validates the company's integrated CRDMO model and deepens its competitive moat in the biologics CDMO space.
Source: prnewswire.com · pannaphat.me
A landmark study reveals that the excruciating tropical disease Chikungunya is now capable of local transmission across most of Europe. Driven by the northward migration of the Aedes albopictus mosquito, this shift creates an urgent demand for vaccines and diagnostic infrastructure in previously unaffected regions.
Source: theguardian.com · aol.co.uk
European Medicines Agency (EMA) is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
